Progyny, Inc. PGNY R2K

Healthcare · Healthcare Plans · United States

https://www.progyny.com

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Market & Price

Market Cap

$2.00B

Current Price

$25.56

High / Low (52W)

$28.42 / $16.30

Beta

0.91

Valuation

Stock P/E

33.19

Industry PE

23.65

Forward P/E

11.58

PEG Ratio

Book Value

$6.24

Price to Book

4.10

P/S

1.55

EV/EBITDA

16.48

Dividend Yield

Profitability & Returns

ROCE

15.79%

ROE

14.94%

ROA

9.12%

Profit Margin

5.24%

Op Margin

10.77%

EPS (Latest Qtr)

$0.29

EPS (TTM)

$0.77

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

2.07

Current Ratio

2.13

Debt

$27.28M

Total Assets

$742.43M

Current Assets

$551.77M

Working Capital

$349.38M

Ownership

Promoter Holding

1.95%

Chg in Prom Hold

FII / Inst Holding

112.19%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$1.80B

Total Revenue (TTM)

$1.29B

EBITDA

$109.51M

Free Cash Flow

$200.21M

Operating Cash Flow

$206.33M

Shares Outstanding

78.33M

Gross Margin

24.11%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

17.87%

Profit 5Y

24.45%

Revenue (YoY)

1.40%

Earnings (YoY)

70.60%

PROS

Compounding revenue at 17.9% over 5 years.
Profit CAGR of 24.5% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PGNY Progyny, Inc. R2K	25.56	33.19	$2.00B	-	15.79%	14.94%	17.87%	24.45%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	122.13M	128.65M	122.28M	127.55M	172.22M	195.00M	205.37M	214.32M	258.39M	279.37M	280.89M	269.94M	278.08M	304.09M	286.62M	298.43M	324.04M	332.87M	313.35M	318.40M	328.50M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	248.24M	253.90M	240.51M	241.52M	245.43M
Gross Profit	3.93M	5.04M	5.05M	5.42M	9.96M	11.45M	12.32M	11.77M	16.60M	11.96M	20.84M	20.67M	28.91M	29.62M	28.49M	25.11M	32.95M	43.89M	45.99M	44.49M	58.64M	60.64M	62.62M	56.89M	62.41M	68.28M	59.24M	63.43M	75.80M	78.97M	72.83M	76.88M	83.07M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	51.62M	54.62M	51.31M	61.66M	47.69M
Operating Income	-1.84M	-317.00K	-587.00K	-703.00K	3.11M	2.35M	3.07M	1.14M	3.43M	-1.07M	4.83M	1.16M	11.81M	11.66M	9.06M	-188.00K	-58.00K	8.84M	11.26M	3.31M	15.01M	15.18M	18.19M	13.80M	18.52M	20.69M	12.46M	15.79M	24.17M	24.36M	21.53M	15.22M	35.38M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.28M	25.56M	22.80M	16.59M	36.86M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.54M	27.08M	23.96M	17.85M	36.88M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.48M	9.96M	10.10M	5.37M	12.65M
Net Income	4.15M	-831.00K	-1.14M	-1.52M	2.52M	1.52M	-8.21M	-4.40M	3.63M	-1.06M	4.82M	39.07M	15.17M	18.73M	16.80M	15.08M	4.97M	8.77M	13.21M	3.41M	17.68M	14.99M	15.90M	13.47M	16.90M	16.48M	10.42M	10.53M	15.06M	17.11M	13.86M	12.48M	24.23M
Diluted EPS	-	-	-	-	0.01	-	-1.10	-0.07	0.04	-0.01	0.05	0.39	0.15	0.19	0.17	0.15	0.05	0.09	0.13	0.03	0.18	0.15	0.16	0.13	0.17	0.17	0.11	0.12	0.17	0.19	0.15	0.14	0.29
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.50M	-	2.60M	-	2.80M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	344.86M	-	786.91M	1.09B	1.17B	1.29B
Cost of Revenue	-	-	-	-	-	619.59M	849.80M	913.86M	984.18M
Gross Profit	7.40M	19.43M	45.51M	70.06M	-	167.32M	238.80M	253.36M	304.48M
Operating Expenses	-	-	-	-	-	143.98M	176.62M	185.91M	219.21M
Operating Income	-11.01M	-3.45M	9.68M	8.35M	-	23.34M	62.18M	67.45M	85.28M
EBITDA	-	-	-	-	-	24.94M	64.47M	70.63M	90.22M
Interest Expense	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	24.44M	70.69M	83.20M	95.43M
Tax Provision	-	-	-	-	-	-5.92M	8.65M	28.87M	36.91M
Net Income	-12.45M	661.00K	-8.57M	46.46M	-	30.36M	62.04M	54.34M	58.52M
Diluted EPS	-2.37	0.04	-0.41	0.47	-	0.30	0.62	0.57	0.65
R&D Expense	-	-	-	-	-	-	-	-	9.50M

Compounded Sales Growth

5 Years:	17.87%
1 Year:	1.40%

Compounded Profit Growth

5 Years:	24.45%
1 Year:	70.60%

Stock Price Performance

1 Year:	+18.88%
6 Months:	-4.52%
3 Months:	+44.49%
1 Month:	+38.76%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	41.32M	150.43M	253.93M	-	542.99M	756.62M	607.10M	742.43M
Current Assets	-	-	-	-	-	433.86M	640.41M	472.72M	551.77M
Cash & Equivalents	-	127.00K	80.38M	70.31M	-	120.08M	97.30M	162.31M	112.24M
Inventory	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	240.07M	241.87M	235.32M	220.29M
Total Liabilities	-	30.20M	36.16M	86.98M	-	166.02M	203.19M	185.04M	226.39M
Current Liabilities	-	30.20M	36.16M	77.79M	-	159.54M	185.95M	168.63M	202.39M
Long Term Debt	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	7.71M	19.39M	19.27M	27.73M
Total Equity	-97.62M	-95.11M	114.27M	166.95M	-	376.97M	553.43M	422.06M	516.04M
Shares Outstanding	-	-	-	-	-	93.92M	96.96M	98.31M	99.67M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-9.47M	2.27M	-1.53M	36.20M	-	80.39M	188.81M	179.10M	210.19M
Investing Cash Flow	-612.00K	1.90M	-2.76M	-40.03M	-	-43.87M	-200.53M	195.79M	-159.01M
Financing Cash Flow	11.77M	-8.74M	84.55M	-6.25M	-	-7.86M	-11.07M	-309.88M	-99.36M
Capital Expenditure	-612.00K	-579.00K	-2.96M	-1.04M	-	-3.24M	-3.64M	-5.41M	-18.41M
Free Cash Flow	-10.09M	1.69M	-4.49M	35.17M	-	77.15M	185.17M	173.70M	191.78M
Net Change in Cash	-	-	-	-	-	28.66M	-22.78M	65.02M	-48.18M
Share Buybacks	-	1.21M	185.00K	-	-	0	0	300.28M	81.66M

Ratios (Annual)

Figures in %.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	20.3%	-	21.3%	21.9%	21.7%	23.6%
Operating Margin %	-	-	-	2.4%	-	3.0%	5.7%	5.8%	6.6%
Net Margin %	-	-	-	13.5%	-	3.9%	5.7%	4.7%	4.5%
ROE %	12.8%	-0.7%	-7.5%	27.8%	-	8.1%	11.2%	12.9%	11.3%
ROCE %	-	-31.0%	8.5%	4.7%	-	6.1%	10.9%	15.4%	15.8%

Shareholding Pattern

Insiders

1.95%

Institutions

112.19%

Public Float

114.43%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.32%	12.00M	$306.68M
2	FMR, LLC	8.30%	6.50M	$166.16M
3	Vanguard Portfolio Management LLC	6.76%	5.29M	$135.26M
4	Vanguard Capital Management LLC	4.44%	3.48M	$88.98M
5	State Street Corporation	3.93%	3.08M	$78.73M
6	Ameriprise Financial, Inc.	3.61%	2.83M	$72.22M
7	Fort Washington Investment Advisors, Inc.	3.44%	2.69M	$68.84M
8	Wellington Management Group, LLP	2.92%	2.29M	$58.47M
9	Morgan Stanley	2.92%	2.29M	$58.47M
10	Soleus Capital Management, L.P.	2.64%	2.07M	$52.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGNY

No recent headlines available.

PGNY · Healthcare

Progyny, Inc.

About

Key Facts

Sector	Healthcare
Industry	Healthcare Plans
Headquarters	United States
Employees	835
Website	https://www.progyny.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Progyny, Inc. PGNY R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More